|
Characteristics of brain natriuretic peptide (BNP) and N-terminal pro-BNP assays |
||||||
| Reference |
BNP/NT-proBNP |
Assay |
Manufacturer |
Kind of assay |
Cutoff, pg/mL |
Elevated BNP, percentage |
|
|
||||||
| Kucher, et al. [1] |
BNP |
Fluorescence immunoassay |
Biosite (San Diego, USA) |
Quantitative |
90 |
43.8 |
| Ten Wolde, et al. [2] |
BNP |
Immunoradiometric assay |
Shionoria (Osaka, Japan) |
Quantitative |
21.7 |
33 |
| Pieralli, et al. [3] |
BNP |
Fluorescence immunoassay |
Biosite |
Quantitative |
527 |
67 |
| Krüger, et al. [4] |
BNP |
Immunofluorometric assay |
Biosite |
Quantitative |
90 |
40 |
| Tulevski, et al. [5] |
BNP |
Immunoradiometric assay |
Shionoria |
Quantitative |
10 |
50 |
| Logeart, et al. [6] |
BNP |
Fluorescence immunoassay |
Biosite |
Quantitative |
100 |
70 |
| Ray, et al. [7] |
BNP |
Fluorescence immunoassay |
BioMérieux (Marcy l'Etoile, France) |
Quantitative |
200 |
43 |
| Pruszczyk, et al. [8] |
NT-proBNP |
ECLIA |
Roche (Basel, Switzerland) |
Quantitative |
NA |
83.5 |
| Kucher, et al. [9] |
NT-proBNP |
ECLIA |
Roche |
Quantitative |
500 |
57 |
| Kostrubiec, et al. [10] |
NT-proBNP |
ECLIA |
Roche |
Quantitative |
600 |
39 |
| Binder, et al. [11] |
NT-proBNP |
ECLIA |
Roche |
Quantitative |
1,000 |
54 |
| Maziere, et al. [12] |
NT-proBNP |
ECLIA |
Roche |
Quantitative |
1,000 |
43 |
|
ECLIA, enhanced chemiluminescence immunoassay; NA, not applicable; NT-proBNP, N-terminal pro-brain natriuretic peptide. Triage BNP test is manufactured by Biosite (San Diego, USA). | ||||||
Coutance et al. Critical Care 2008 12:R109 doi:10.1186/cc6996 |
||||||